期刊文献+

XPG基因多态性与奥沙利铂治疗晚期胃癌疗效相关性的研究(英文) 被引量:2

Study on the relationship between polymorphisms in xpg gene and therapeutic effect of oxaliplatin for advanced gastric cancer
原文传递
导出
摘要 目的:研究人着色性干皮病G组(XPG)C46T与奥沙利铂治疗晚期胃癌敏感性的关系。方法:用REAL-TIMEPCR技术检测92例晚期胃癌患者外周静脉血DNA的XPG基因的单核苷多态性(SNP)分型。比较三种基因型与奥沙利铂化疗后患者的2周期化疗临床疗效、中位疾病进展时间(TTP)的关系。结果:92例患者的C/C、T/T、C/T基因型分别为51.09%(47/92)、38.04%(35/92)、10.87%(10/92),C/C与T/T+C/T基因型2周期临床获益率和中位TTP分别为76.59%、6个月和53.33%、4个月,C/C基因型的临床获益率和中位TTP均优于T/T+C/T基因型。结论:XPG基因多态性与奥沙利铂疗效之间存在相关性,其检测结果可以指导胃癌选择奥沙利铂化疗。 Objective:To investigate the relationship between polymorphisms in XPG gene C46T and therapeutic effect of oxaliplatin for advanced gastric cancer.Methods:The types of XPG single nucleotide polymorphisms (SNPs) of DNA from peripheral venous blood were detected by Real-time PCR.The relationships of three genotypes'chemotherapy effect after two cycles of chemotherapy and the median time to progression were compared.Results:The effect rates of the three genotypes are:C/C 51.09%(47/92), C/T 38.04% (35/92), and T/T 10.87%(10/92), while the clinical benefit rates of chemotherapy and the median TTP of C/C and T/T+C/T genotypes were 76.59% , 6 months and 53.33%, 4 months, respectively.Conclusions:There is relationship between polymorphisms in XPG gene and therapeutic effect of oxaliplatin, which could be used as a guidance of the medication of oxaliplatin chemotherapy for gastric cancer.
出处 《现代生物医学进展》 CAS 2010年第14期2615-2618,共4页 Progress in Modern Biomedicine
基金 Natural Science Foundation of Shandong Province(Y2008C126)~~
关键词 XPG 基因多态性 胃癌 奥沙利铂 XPG Gastric carcinoma Polymorphism Single nucleotide Polymorphism Oxaliplatin
  • 引文网络
  • 相关文献

参考文献2

二级参考文献9

  • 1张静,赵海青.结肠癌PTEN基因点突变的PCR-SSCP检测[J].齐鲁医学杂志,2004,19(6):474-476. 被引量:4
  • 2温树信,唐平章,张雪梅,赵丹,郭永丽,谭文,林东昕.着色性干皮病G组基因多态性与喉癌和喉咽癌风险的相关性[J].中国医学科学院学报,2006,28(5):703-706. 被引量:3
  • 3于庆忠,韩金祥,潘继红,盛立军,吴坚美,黄海南.NSCLC患者XPG、MDR-1基因单核苷酸多态性与铂类药物化疗疗效的关系[J].山东医药,2007,47(9):7-9. 被引量:4
  • 4FUJITA K,SASAKI Y.Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy[J].Curr Drug Metab,2007,8(6):554-562. 被引量:1
  • 5VILA J M,MORENO I,MONZO M,et al.XPD,XPA,ERCC1 and XPG/ERCC5 single nucleotide polymorphisms (SNPs) in oxaliplatin-treated colorectal cancer (CRC)[J].J Clin Oncol,2004,22:3677. 被引量:1
  • 6ARAUJO S J,NIGG E A,WOOD R D.Strong functional interactions of the TFIIH with XPC and XPG in human DNA nucleotide excision repair without a preassembled repairosome[J].Mol Cell Biol,2001,21:2281-2291. 被引量:1
  • 7VAN STEEG H,KRAEMER K H.Xeroderma pigmentosum and the role of UV induced DNA damage in skin cancer[J].Mol Med Today,1999,5:86-94. 被引量:1
  • 8JEON H S,KIM K M,PARK S H,et al.Relationship between XPG codon 1104 polymorphism and risk of primary lung cancer[J].Carcinogenesis,2003,24(10):1677-1681. 被引量:1
  • 9MONZO M,MORENO I,NAVARROO A,et al.Single nucleotide polymorphisms in nucleotide excision repair genes XPA,XPD,XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine[J].Oncology,2007,72(5-6):364-370. 被引量:1

共引文献436

同被引文献16

引证文献2

二级引证文献34

;
使用帮助 返回顶部